GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » YoY EBITDA Growth

Inotiv (STU:BS50) YoY EBITDA Growth : -350.60% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inotiv YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Inotiv's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -350.60%.

Inotiv's EBITDA per Share for the three months ended in Mar. 2024 was €-1.04.


Inotiv YoY EBITDA Growth Historical Data

The historical data trend for Inotiv's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv YoY EBITDA Growth Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.62 -64.44 978.75 -1,413.90 91.45

Inotiv Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.13 2.03 107.65 107.67 -350.60

Inotiv YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Inotiv's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (A: Sep. 2023 )
=(EBITDA per Share (A: Sep. 2023 )-EBITDA per Share (A: Sep. 2022 ))/ | EBITDA per Share (A: Sep. 2022 ) |
=(-0.969--11.339)/ | -11.339 |
=91.45 %

Inotiv's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-1.04-0.415)/ | 0.415 |
=-350.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inotiv YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Inotiv's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (STU:BS50) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines